|
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
|
07 July 2022 |
|
Boehringer Ingelheim signs option to acquire Trutino Biosciences
|
15 June 2022 |
|
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
|
03 March 2022 |
|
EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
|
13 December 2021 |
|
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
|
27 September 2021 |
|
Europe's largest initiative launches to accelerate therapy development for COVID-19 and future coronavirus threats
|
26 August 2020 |
|
New consortium EUbOPEN will provide tools to unlock disease biology
|
09 June 2020 |
|
Boehringer Ingelheim steps up effort with Global Support Program
|
15 April 2020 |
|
Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases
|
10 January 2020 |
|
Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing
|
31 October 2019 |
|
Boehringer Ingelheim eExpands KRAS cancer program with Lupin's clinical stage MEK inhibitor compound
|
05 September 2019 |
|
Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients
|
30 August 2019 |
|
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
|
13 August 2019 |
|
Boehringer Ingelheim acquires AMAL Therapeutics, significantly enriching its cancer immunology portfolio with novel cancer vaccines platform
|
15 July 2019 |
|
Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
|
11 June 2019 |
|
Boehringer Ingelheim announces finalists of the Making More Health Accelerator Program
|
10 May 2019 |
|
Independent large real-world study comparing NOACs in AF-patients
|
16 April 2019 |
|
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics
|
05 April 2019 |
|
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
|
26 March 2019 |
|
Boehringer Ingelheim (Canada) Ltd. and IBM Canada announce first of its kind collaboration to integrate blockchain technology into clinical trials
|
13 February 2019 |